Revelation BioSciences
HOME CONTACT
PIPELINE CLINICAL TRIALS
News 2025 Annual Report Presentation ROTH 2026 WEBCAST CRRT Poster PRIME Data Stock Ticker SEC EDGAR
About Us Board of Directors Management Scientific Advisory Board Core Values
HOME PIPELINE & PROGRAMS PIPELINE CLINICAL TRIALS INVESTORS News 2025 Annual Report Presentation ROTH 2026 WEBCAST CRRT Poster PRIME Data Stock Ticker SEC EDGAR ABOUT US About Us Board of Directors Management Scientific Advisory Board Core Values CONTACT
Revelation BioSciences

James PhillipsAugust 3, 2026
Twitter LinkedIn0 0 Likes
Previous

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

James PhillipsAugust 3, 2026
Next

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

James PhillipsJuly 21, 2026
 
 

Subscribe

Sign up with your email address to receive news and updates.

Thank you!
 
Terms of UsePrivacy

© 2026 Revelation BioSciences